个人中心 - 老虎社区

oyzheng

IP属地：未知

帖子 · 15帖子 · 15
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- oyzhengoyzheng
  ·2021-06-15
  Looks good
  Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up<blockquote>Novavax与辉瑞与Moderna：COVID-19疫苗如何叠加</blockquote>
  It was "better late than never" for Novavax, Inc.NVAX, as the biopharma finally got around to announ
  Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up<blockquote>Novavax与辉瑞与Moderna：COVID-19疫苗如何叠加</blockquote>
  1,013 评论
  2
  分享
  举报
- oyzhengoyzheng
  ·2021-06-15
  Nice
  非常抱歉，此主贴已删除
  927 评论
  1
  分享
  举报
- oyzhengoyzheng
  ·2021-06-14
  Good read
  非常抱歉，此主贴已删除
  867 评论
  2
  分享
  举报
- oyzhengoyzheng
  ·2021-06-14
  Oh no!
  非常抱歉，此主贴已删除
  1,484 评论
  1
  分享
  举报
- oyzhengoyzheng
  ·2021-06-14
  Good info
  PayPal: One Of The Best Plays On The Secular Growth Trend Of Digital Payments<blockquote>PayPal：数字支付长期增长趋势的最佳剧本之一</blockquote>
  Summary PayPal is a leading fintech company that benefits immensely from the secular growth trend i
  PayPal: One Of The Best Plays On The Secular Growth Trend Of Digital Payments<blockquote>PayPal：数字支付长期增长趋势的最佳剧本之一</blockquote>
  727 评论
  点赞
  分享
  举报
- oyzhengoyzheng
  ·2021-06-14
  Nice
  非常抱歉，此主贴已删除
  1,360 评论
  1
  分享
  举报
- oyzhengoyzheng
  ·2021-06-14
  I agree
  非常抱歉，此主贴已删除
  2,012 评论
  5
  分享
  举报
- oyzhengoyzheng
  ·2021-06-12
  Interesting
  非常抱歉，此主贴已删除
  820 评论
  点赞
  分享
  举报
- oyzhengoyzheng
  ·2021-06-12
  Oh no
  非常抱歉，此主贴已删除
  2,061 评论
  点赞
  分享
  举报
- oyzhengoyzheng
  ·2021-06-12
  Good info
  非常抱歉，此主贴已删除
  2,385 评论
  点赞
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3575704006877751","uuid":"3575704006877751","gmtCreate":1612612352712,"gmtModify":1612612352712,"name":"oyzheng","pinyin":"oyzheng","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":1,"tweetSize":15,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.12.28","exceedPercentage":"60.36%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.50%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":187654423,"gmtCreate":1623753263762,"gmtModify":1634029019236,"author":{"id":"3575704006877751","authorId":"3575704006877751","name":"oyzheng","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575704006877751","idStr":"3575704006877751"},"themes":[],"htmlText":"Looks good","listText":"Looks good","text":"Looks good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187654423","repostId":"1167457915","repostType":4,"repost":{"id":"1167457915","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623750756,"share":"https://www.laohu8.com/m/news/1167457915?lang=zh_CN&edition=full","pubTime":"2021-06-15 17:52","market":"us","language":"en","title":"Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up<blockquote>Novavax与辉瑞与Moderna：COVID-19疫苗如何叠加</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1167457915","media":"Benzinga","summary":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announ","content":"<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p><p><blockquote>“迟到总比不到好”<b>诺瓦瓦克斯公司。</b>NVAX，这家生物制药公司终于抽出时间宣布了NVX-CoV2371（其针对新型冠状病毒病的候选疫苗）3期研究美国和墨西哥部分的中期结果。</blockquote></p><p> Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p><p><blockquote>以下是Novavax候选疫苗和领跑者的比较视角，即<b>辉瑞公司。</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>莫德纳公司。</b>MRNA，两者都有授权疫苗上市。</blockquote></p><p> <b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p><p><blockquote><b>疫苗类型：</b>Novavax的NVX-CoV2371是一种基于重组纳米颗粒蛋白的COVID-19疫苗，与该公司专有的Matrix-M佐剂包装在一起。</blockquote></p><p> The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p><p><blockquote>辉瑞-BioNTech和Moderna的产品是mRNA疫苗，或通过使用一种称为mRNA的遗传密码来发挥作用的现代疫苗，这种遗传密码指示我们的免疫细胞制造刺突蛋白，刺突蛋白存在于导致新冠肺炎的病毒表面。</blockquote></p><p> This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p><p><blockquote>这种刺突蛋白虽然无害，但能够触发我们的免疫系统产生抗体，防止未来的感染。</blockquote></p><p> Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p><p><blockquote>Novavax的疫苗是一种蛋白质佐剂，含有冠状病毒本身的刺突蛋白，但配方为纳米颗粒，不会导致疾病。然后，注射的疫苗刺激免疫系统产生抗体和T细胞免疫反应。</blockquote></p><p> <b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p><p><blockquote><b>疫苗剂量：</b>这三家公司的疫苗都需要接种两剂。辉瑞的每剂由30 mcg和Moderna的100 mcg组成，而Novavax的每剂疫苗由5 mcg NVX-CoV2371和50 mcg Matrix-M1佐剂组成，它们是共同配制的。</blockquote></p><p> The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p><p><blockquote>辉瑞和Novavax的两种剂量（初免剂量和加强剂量）之间的间隔为21天，Moderna为28天。</blockquote></p><p> <b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p><p><blockquote><b>目标人群：</b>辉瑞-BioNTech最初的后期试验在16岁及以上的参与者中评估了疫苗。该试验招募了43,448名参与者。</blockquote></p><p> Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p><p><blockquote>Moderna的3期COVE研究招募了30,000名18岁及以上的参与者。</blockquote></p><p> Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p><p><blockquote>此后，这两家公司获得了各自疫苗用于青少年的授权。</blockquote></p><p> Bothcompanieshave also initiated studies in the pediatric population.</p><p><blockquote>两家公司还启动了针对儿科人群的研究。</blockquote></p><p> Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p><p><blockquote>Novavax的研究在美国和墨西哥的119个地点招募了29,960名18岁及以上的参与者。PREVENT-19的安慰剂对照部分继续在12岁至18岁以下的青少年中进行，最近完成了2,248名参与者的招募。</blockquote></p><p> <b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p><p><blockquote><b>疫苗物流：</b>辉瑞公司最近获得了FDA的授权，可以将未稀释、解冻的疫苗瓶在2°C至8°C的冰箱中储存长达一个月。</blockquote></p><p> Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p><p><blockquote>以前，解冻、未稀释的疫苗瓶可以在冰箱中储存长达五天。Moderna的疫苗在首次使用前可以在2至8°C的冰箱中储存长达30天。</blockquote></p><p> NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p><p><blockquote>NVX-CoV2373在2°-8°C下储存稳定，允许使用现有的疫苗供应链渠道进行分销。它被包装在10剂小瓶中的即用型液体制剂中。</blockquote></p><p> <b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p><p><blockquote><b>疫苗效力：</b>辉瑞-BioNTech去年12月发布的3期试验中期数据显示，该疫苗耐受性良好，在第二剂疫苗接种后7天或更长时间内，在预防新冠肺炎方面表现出95%的疗效。第二次给药后长达六个月发布的更新顶线结果证实疗效为91.3%。</blockquote></p><p> The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p><p><blockquote>该疫苗被发现对美国疾病控制和预防中心定义的严重疾病100%有效，对FDA定义的严重新冠肺炎95.3%有效。在实验室研究中，它也被证明对英国菌株有效。</blockquote></p><p> Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p><p><blockquote>Moderna的疫苗对新冠肺炎的有效性为94.1%。该公司于5月宣布了其2期研究的初步数据，显示向先前接种疫苗的个体给予50微克剂量的mRNA-1273或mRNA-1273.351作为加强剂，增加了针对新型冠状病毒病毒和两种令人担忧的变异体的中和抗体滴度反应，B.1.351，首次在南非发现，P.1，首次在巴西发现。</blockquote></p><p> Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p><p><blockquote>Novavax的研究疫苗对中度和重度疾病表现出100%的保护作用，不涉及令人担忧的变异体或感兴趣的变异体。</blockquote></p><p> Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p><p><blockquote>针对关注变异体和感兴趣变异体，疗效为93.2%，在高危人群（定义为65岁以上或65岁以下，患有某些合并症或经常暴露于新冠肺炎的情况）中，疗效为91%。</blockquote></p><p> Overall efficacy was 90.4%, meeting the primary endpoint.</p><p><blockquote>总疗效为90.4%，达到主要终点。</blockquote></p><p></p><p> <b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p><p><blockquote><b>坎托·菲茨杰拉德谈Novavax的疫苗：</b>Cantor Fitzgerald分析师Charles Duncan在周一早间报告中表示，NVX-2373的一个与众不同之处在于，它对VoC/VoI表现出93.2%的疫苗效力，这证明了对多种新型冠状病毒毒株的保护作用。</blockquote></p><p> \"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p><p><blockquote>该分析师表示：“总体而言，这些结果增强了我们对新型冠状病毒候选疫苗‘2373具有差异化临床和物流特征的信念。”</blockquote></p><p> Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p><p><blockquote>他说，在两项3期临床试验中显示出对新毒株的功效，而不是从培养皿中进行的中和抗体测定中推断出潜在功效，这将NVX-CoV2373与其他获得紧急使用授权的疫苗区分开来。</blockquote></p><p> This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p><p><blockquote>Cantor表示，这一概况降低了'2373新型冠状病毒预防性候选疫苗的监管/商业风险，并且随着2020年3月报告的NanoFlu 3期积极数据，应该会提高Novavax平台的整体形象。</blockquote></p><p> <b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p><p><blockquote><b>疫苗安全性数据：</b>辉瑞-BioNTech的疫苗显示出良好的耐受性和安全性，BNT 162 B 2最常见的不良事件是注射部位的短暂、轻度至中度疼痛、疲劳和头痛，这些通常在两天内消退。</blockquote></p><p> For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p><p><blockquote>对于Moderna，最常见的不良反应包括注射部位疼痛、疲劳、肌痛、关节痛、头痛和注射部位红斑/发红。在第二次给药后，mRNA-1273组中引起的不良反应的频率和严重程度增加。</blockquote></p><p> Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p><p><blockquote>Novavax试验的初步安全性数据显示，该疫苗总体耐受性良好。严重和严重不良事件的数量较少，并且在疫苗组和安慰剂组之间平衡。</blockquote></p><p> In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p><p><blockquote>在第1剂和第2剂后7天评估反应原性时，注射部位疼痛和压痛（通常严重程度为轻度至中度）是最常见的局部症状，持续时间少于3天。疲劳、头痛和肌肉疼痛是最常见的全身症状，持续时间不到两天。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up<blockquote>Novavax与辉瑞与Moderna：COVID-19疫苗如何叠加</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up<blockquote>Novavax与辉瑞与Moderna：COVID-19疫苗如何叠加</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-06-15 17:52</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p><p><blockquote>“迟到总比不到好”<b>诺瓦瓦克斯公司。</b>NVAX，这家生物制药公司终于抽出时间宣布了NVX-CoV2371（其针对新型冠状病毒病的候选疫苗）3期研究美国和墨西哥部分的中期结果。</blockquote></p><p> Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p><p><blockquote>以下是Novavax候选疫苗和领跑者的比较视角，即<b>辉瑞公司。</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>莫德纳公司。</b>MRNA，两者都有授权疫苗上市。</blockquote></p><p> <b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p><p><blockquote><b>疫苗类型：</b>Novavax的NVX-CoV2371是一种基于重组纳米颗粒蛋白的COVID-19疫苗，与该公司专有的Matrix-M佐剂包装在一起。</blockquote></p><p> The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p><p><blockquote>辉瑞-BioNTech和Moderna的产品是mRNA疫苗，或通过使用一种称为mRNA的遗传密码来发挥作用的现代疫苗，这种遗传密码指示我们的免疫细胞制造刺突蛋白，刺突蛋白存在于导致新冠肺炎的病毒表面。</blockquote></p><p> This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p><p><blockquote>这种刺突蛋白虽然无害，但能够触发我们的免疫系统产生抗体，防止未来的感染。</blockquote></p><p> Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p><p><blockquote>Novavax的疫苗是一种蛋白质佐剂，含有冠状病毒本身的刺突蛋白，但配方为纳米颗粒，不会导致疾病。然后，注射的疫苗刺激免疫系统产生抗体和T细胞免疫反应。</blockquote></p><p> <b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p><p><blockquote><b>疫苗剂量：</b>这三家公司的疫苗都需要接种两剂。辉瑞的每剂由30 mcg和Moderna的100 mcg组成，而Novavax的每剂疫苗由5 mcg NVX-CoV2371和50 mcg Matrix-M1佐剂组成，它们是共同配制的。</blockquote></p><p> The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p><p><blockquote>辉瑞和Novavax的两种剂量（初免剂量和加强剂量）之间的间隔为21天，Moderna为28天。</blockquote></p><p> <b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p><p><blockquote><b>目标人群：</b>辉瑞-BioNTech最初的后期试验在16岁及以上的参与者中评估了疫苗。该试验招募了43,448名参与者。</blockquote></p><p> Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p><p><blockquote>Moderna的3期COVE研究招募了30,000名18岁及以上的参与者。</blockquote></p><p> Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p><p><blockquote>此后，这两家公司获得了各自疫苗用于青少年的授权。</blockquote></p><p> Bothcompanieshave also initiated studies in the pediatric population.</p><p><blockquote>两家公司还启动了针对儿科人群的研究。</blockquote></p><p> Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p><p><blockquote>Novavax的研究在美国和墨西哥的119个地点招募了29,960名18岁及以上的参与者。PREVENT-19的安慰剂对照部分继续在12岁至18岁以下的青少年中进行，最近完成了2,248名参与者的招募。</blockquote></p><p> <b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p><p><blockquote><b>疫苗物流：</b>辉瑞公司最近获得了FDA的授权，可以将未稀释、解冻的疫苗瓶在2°C至8°C的冰箱中储存长达一个月。</blockquote></p><p> Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p><p><blockquote>以前，解冻、未稀释的疫苗瓶可以在冰箱中储存长达五天。Moderna的疫苗在首次使用前可以在2至8°C的冰箱中储存长达30天。</blockquote></p><p> NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p><p><blockquote>NVX-CoV2373在2°-8°C下储存稳定，允许使用现有的疫苗供应链渠道进行分销。它被包装在10剂小瓶中的即用型液体制剂中。</blockquote></p><p> <b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p><p><blockquote><b>疫苗效力：</b>辉瑞-BioNTech去年12月发布的3期试验中期数据显示，该疫苗耐受性良好，在第二剂疫苗接种后7天或更长时间内，在预防新冠肺炎方面表现出95%的疗效。第二次给药后长达六个月发布的更新顶线结果证实疗效为91.3%。</blockquote></p><p> The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p><p><blockquote>该疫苗被发现对美国疾病控制和预防中心定义的严重疾病100%有效，对FDA定义的严重新冠肺炎95.3%有效。在实验室研究中，它也被证明对英国菌株有效。</blockquote></p><p> Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p><p><blockquote>Moderna的疫苗对新冠肺炎的有效性为94.1%。该公司于5月宣布了其2期研究的初步数据，显示向先前接种疫苗的个体给予50微克剂量的mRNA-1273或mRNA-1273.351作为加强剂，增加了针对新型冠状病毒病毒和两种令人担忧的变异体的中和抗体滴度反应，B.1.351，首次在南非发现，P.1，首次在巴西发现。</blockquote></p><p> Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p><p><blockquote>Novavax的研究疫苗对中度和重度疾病表现出100%的保护作用，不涉及令人担忧的变异体或感兴趣的变异体。</blockquote></p><p> Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p><p><blockquote>针对关注变异体和感兴趣变异体，疗效为93.2%，在高危人群（定义为65岁以上或65岁以下，患有某些合并症或经常暴露于新冠肺炎的情况）中，疗效为91%。</blockquote></p><p> Overall efficacy was 90.4%, meeting the primary endpoint.</p><p><blockquote>总疗效为90.4%，达到主要终点。</blockquote></p><p></p><p> <b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p><p><blockquote><b>坎托·菲茨杰拉德谈Novavax的疫苗：</b>Cantor Fitzgerald分析师Charles Duncan在周一早间报告中表示，NVX-2373的一个与众不同之处在于，它对VoC/VoI表现出93.2%的疫苗效力，这证明了对多种新型冠状病毒毒株的保护作用。</blockquote></p><p> \"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p><p><blockquote>该分析师表示：“总体而言，这些结果增强了我们对新型冠状病毒候选疫苗‘2373具有差异化临床和物流特征的信念。”</blockquote></p><p> Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p><p><blockquote>他说，在两项3期临床试验中显示出对新毒株的功效，而不是从培养皿中进行的中和抗体测定中推断出潜在功效，这将NVX-CoV2373与其他获得紧急使用授权的疫苗区分开来。</blockquote></p><p> This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p><p><blockquote>Cantor表示，这一概况降低了'2373新型冠状病毒预防性候选疫苗的监管/商业风险，并且随着2020年3月报告的NanoFlu 3期积极数据，应该会提高Novavax平台的整体形象。</blockquote></p><p> <b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p><p><blockquote><b>疫苗安全性数据：</b>辉瑞-BioNTech的疫苗显示出良好的耐受性和安全性，BNT 162 B 2最常见的不良事件是注射部位的短暂、轻度至中度疼痛、疲劳和头痛，这些通常在两天内消退。</blockquote></p><p> For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p><p><blockquote>对于Moderna，最常见的不良反应包括注射部位疼痛、疲劳、肌痛、关节痛、头痛和注射部位红斑/发红。在第二次给药后，mRNA-1273组中引起的不良反应的频率和严重程度增加。</blockquote></p><p> Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p><p><blockquote>Novavax试验的初步安全性数据显示，该疫苗总体耐受性良好。严重和严重不良事件的数量较少，并且在疫苗组和安慰剂组之间平衡。</blockquote></p><p> In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p><p><blockquote>在第1剂和第2剂后7天评估反应原性时，注射部位疼痛和压痛（通常严重程度为轻度至中度）是最常见的局部症状，持续时间少于3天。疲劳、头痛和肌肉疼痛是最常见的全身症状，持续时间不到两天。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167457915","content_text":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.\nHere's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namelyPfizer Inc.PFE 0.05%-BioNTech SEBNTXandModerna, Inc.MRNA, both of which have authorized vaccines in the market.\nVaccine Type: Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.\nThe Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.\nThis spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.\nNovavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.\nThe Vaccine Doses: The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.\nThe interval between the two doses — the priming and booster dose — is 21 days each for Pfizer and Novavax and 28 days for Moderna.\nThe Target Population: The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants ages 16 years and older. The trial enrolled 43,448 participants.\nModerna'sPhase 3 COVE study enrolled 30,000 participants ages 18 years and up.\nSince then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.\nBothcompanieshave also initiated studies in the pediatric population.\nNovavax's study enrolled 29,960 participants 18 years of age and older across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.\nVaccine Logistics: Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.\nPreviously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.\nNVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.\nVaccine Efficacy: Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.\nThe vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.\nModerna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.\nNovavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.\nAgainst variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.\nOverall efficacy was 90.4%, meeting the primary endpoint.\nCantor Fitzgerald On Novavax's Vaccine:A differentiating factor for NVX-2373 is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.\n\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.\nShowing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.\nThis profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.\nVaccine Safety Data:Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.\nFor Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.\nPreliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.\nIn assessing reactogenicity seven days after dose one and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.","news_type":1,"symbols_score_info":{"PFE":0.9,"NVAX":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1013,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187656147,"gmtCreate":1623753166989,"gmtModify":1634029022357,"author":{"id":"3575704006877751","authorId":"3575704006877751","name":"oyzheng","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575704006877751","idStr":"3575704006877751"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187656147","repostId":"1142697857","repostType":4,"isVote":1,"tweetType":1,"viewCount":927,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185214446,"gmtCreate":1623652948485,"gmtModify":1634030606220,"author":{"id":"3575704006877751","authorId":"3575704006877751","name":"oyzheng","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575704006877751","idStr":"3575704006877751"},"themes":[],"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185214446","repostId":"2143785982","repostType":4,"isVote":1,"tweetType":1,"viewCount":867,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185214225,"gmtCreate":1623652934867,"gmtModify":1634030606466,"author":{"id":"3575704006877751","authorId":"3575704006877751","name":"oyzheng","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575704006877751","idStr":"3575704006877751"},"themes":[],"htmlText":"Oh no!","listText":"Oh no!","text":"Oh no!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185214225","repostId":"2143789794","repostType":4,"isVote":1,"tweetType":1,"viewCount":1484,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185214328,"gmtCreate":1623652907864,"gmtModify":1634030606812,"author":{"id":"3575704006877751","authorId":"3575704006877751","name":"oyzheng","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575704006877751","idStr":"3575704006877751"},"themes":[],"htmlText":"Good info","listText":"Good info","text":"Good info","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185214328","repostId":"1141995531","repostType":4,"repost":{"id":"1141995531","kind":"news","pubTimestamp":1623652578,"share":"https://www.laohu8.com/m/news/1141995531?lang=zh_CN&edition=full","pubTime":"2021-06-14 14:36","market":"us","language":"en","title":"PayPal: One Of The Best Plays On The Secular Growth Trend Of Digital Payments<blockquote>PayPal：数字支付长期增长趋势的最佳剧本之一</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1141995531","media":"seekingalpha","summary":"Summary\n\nPayPal is a leading fintech company that benefits immensely from the secular growth trend i","content":"<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>PayPal is a leading fintech company that benefits immensely from the secular growth trend in the digital payments industry.</li>  <li>Its growth history is impressive and momentum is not showing any sign of slowing down, making its 2025 targets quite achievable.</li>  <li>The premium valuation to Visa or Mastercard is justified and PayPal is now my largest holding in the digital payments theme.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/aa4976c13e5ffab4c5035b08d60831ed\" tg-width=\"768\" tg-height=\"512\"><span>JasonDoiy/iStock Unreleased via Getty Images</span></p><p><blockquote><ul><li>PayPal是一家领先的金融科技公司，从数字支付行业的长期增长趋势中受益匪浅。</li><li>其增长历史令人印象深刻，而且势头没有任何放缓的迹象，这使得其2025年的目标完全可以实现。</li><li>Visa或Mastercard的溢价估值是合理的，PayPal现在是我在数字支付主题中最大的持股。</li></ul><p class=\"t-img-caption\"><span>JasonDoiy/iStock未通过Getty Images发布</span></p></blockquote></p><p> <b>PayPal</b>(PYPL) is a compelling long-term play on the secular growth trend of digital payments as the company’s growth path is likely to remain quite strong over the next few years.</p><p><blockquote><b>PayPal</b>（PYPL）是数字支付长期增长趋势中引人注目的长期投资，因为该公司的增长路径在未来几年可能会保持相当强劲。</blockquote></p><p> <b>Company Profile</b></p><p><blockquote><b>公司简介</b></blockquote></p><p> PayPal Holdings Inc. is a leading fintech company that enables digital and mobile payments through its technology platform. Its major competitors are other payment technology companies, such as<b>Visa</b>(V),<b>Mastercard</b>(MA) or<b>Adyen</b>(OTCPK:ADYEY). It currently has a market capitalization of about $309 billion, a smaller value than MasterCard or Visa.</p><p><blockquote>PayPal控股公司是一家领先的金融科技公司，通过其技术平台实现数字和移动支付。其主要竞争对手是其他支付技术公司，如<b>签证</b>(V)，<b>万事达卡</b>（MA）或<b>Adyen</b>（OTCPK：ADYEY）。它目前的市值约为3090亿美元，低于万事达卡或Visa。</blockquote></p><p> PayPal’s core business is the offering of payment solutions to merchants and consumers, operating globally. At the end of 2020, it had about 377 million active accounts, of which some 348 million consumer accounts and 29 million merchant accounts, more than double the number of active accounts at the end of 2015.</p><p><blockquote>PayPal的核心业务是向商家和消费者提供支付解决方案，业务遍及全球。截至2020年底，其拥有约3.77亿活跃账户，其中约3.48亿消费者账户和2900万商家账户，是2015年底活跃账户数量的两倍多。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/45f478cd622b0c634fd146fdf46bf0ef\" tg-width=\"747\" tg-height=\"432\"><span>Source: PayPal.</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：PayPal。</span></p></blockquote></p><p> The company’s revenue stream comes mainly from charging fees for some completed payment transactions, while generally it does not charge consumers to fund or withdraw money from their PayPal account. It also generates revenues from currency conversion and instant transfers from the PayPal or Venmo accounts to debit cards or bank accounts. For its merchant clients, it also offers access to certain credit products for small and medium-sized merchants, increasing its engagement its clients and providing finance for clients that possibly would not get loans from traditional banks or other lending providers.</p><p><blockquote>该公司的收入来源主要来自对一些已完成的支付交易收取费用，而通常不会向消费者收取从其PayPal账户中提供资金或提款的费用。它还通过货币兑换和从PayPal或Venmo账户到借记卡或银行账户的即时转账产生收入。对于其商户客户，它还为中小型商户提供某些信贷产品，增加其客户参与度，并为可能无法从传统银行或其他贷款提供商获得贷款的客户提供融资。</blockquote></p><p> <b>Secular Growth</b></p><p><blockquote><b>长期增长</b></blockquote></p><p> As I’ve analyzed in a previous article on “Visa: Despite Earnings Dip, Secular Growth Prospects Remain Strong,” the global payments industry has a very good growth track record and future growth prospects are quite strong.</p><p><blockquote>正如我在上一篇关于“Visa：尽管盈利下降，长期增长前景依然强劲”的文章中所分析的那样，全球支付行业拥有非常好的增长记录，未来的增长前景也相当强劲。</blockquote></p><p> During the past few years, consumers and businesses have increasingly adopted new payment methods beyond cash and the rise of e-commerce has also been an important growth driver of digital payments across the globe. Revenues for the industry have grown roughly at 7% per year over recent years, to a total of just under $2 trillion in 2019, according to McKinsey data, and this growth is only expected to accelerate in the future as digital payments continue to increase their market share as a percentage of total banking revenues.</p><p><blockquote>在过去几年中，消费者和企业越来越多地采用现金以外的新支付方式，电子商务的兴起也是全球数字支付的重要增长动力。根据麦肯锡的数据，近年来该行业的收入以每年约7%的速度增长，2019年总额略低于2万亿美元，而且随着数字支付继续增加，这种增长预计未来只会加速。市场份额占银行总收入的百分比。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d27b37a2ed30f39bff844ae07aa49ac5\" tg-width=\"372\" tg-height=\"395\"><span>Source: McKinsey.</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：麦肯锡。</span></p></blockquote></p><p> This background has been very supportive for PayPal’s growth prospects, as one of the leading companies in this industry. Indeed, PayPal’s revenues have increased at a compounded annual growth rate [CAGR] of 20.8% during the past five years, a much higher growth rate than the global payments industry and also above its largest competitors like Visa and MasterCard.</p><p><blockquote>作为该行业的领先公司之一，这一背景非常支持PayPal的增长前景。事实上，PayPal的收入在过去五年中以20.8%的复合年增长率[CAGR]增长，远高于全球支付行业的增长率，也高于Visa和MasterCard等最大竞争对手。</blockquote></p><p> Moreover, while recently the growth path of digital payments has changed due to the coronavirus pandemic, that has affected negatively the growth of the global payments industry, PayPal has remained on a strong growth path because its business is clearly more exposed to digital transactions rather than physical payments. This means that the pandemic has barely impacted its business, while it has been a significant setback for other companies, such as&nbsp;<b>American Express</b>&nbsp;(AXP) or MasterCard that are more exposed to cross-border transactions.</p><p><blockquote>此外，虽然最近由于冠状病毒大流行，数字支付的增长路径发生了变化，这对全球支付行业的增长产生了负面影响，但PayPal仍然处于强劲的增长路径上，因为其业务显然更多地暴露于数字交易而不是实物支付。这意味着疫情几乎没有影响其业务，而对其他公司来说却是一个重大挫折，例如<b>美国运通</b>（AXP）或万事达卡更容易进行跨境交易。</blockquote></p><p> Nevertheless, the Covid-19 seems to be positive for the long-term growth of the industry because digital payments became more adopted last year and people will likely use less cash for payment transactions in the future, accelerating even further the growth of digital payments across the world.</p><p><blockquote>尽管如此，新冠肺炎似乎对该行业的长期增长是积极的，因为去年数字支付被更多地采用，人们在未来可能会减少使用现金进行支付交易，从而进一步加速全球数字支付的增长。</blockquote></p><p> Over the next few years, growth is expected to resume quite rapidly and should even be higher than in the recent past. According to Mordor Intelligence, the global digital payments industry is expected to have a revenue CAGR of 13.7% during 2021-26, which is almost double the growth in recent years. This clearly shows that digital payments is a secular growth industry, being a very good backdrop for the companies operating in this industry for years to come.</p><p><blockquote>在未来几年，预计增长将相当迅速地恢复，甚至应该高于最近的过去。根据Mordor Intelligence的数据，预计2021-26年全球数字支付行业的收入CAGR将达到13.7%，几乎是近年来增长的两倍。这清楚地表明，数字支付是一个长期增长的行业，对于未来几年在该行业运营的公司来说是一个非常好的背景。</blockquote></p><p></p><p> Taking this environment into account, PayPal is clearly in a very good position to maintain a solid growth path for many years to come, being potentially one of the major winners of the global shift to digital payments and e-commerce.</p><p><blockquote>考虑到这种环境，PayPal显然处于非常有利的地位，可以在未来许多年保持稳健的增长道路，有可能成为全球向数字支付和电子商务转变的主要赢家之一。</blockquote></p><p> Taking this background into account, it is not surprising that PayPal has strong growth ambitions for the coming years, aiming to generate more than $50 billion in revenue by 2025 (more than double the 2020 revenues) both from growth of its existing business, higher customer engagement and new offerings that will increase PayPal’s total addressable market.</p><p><blockquote>考虑到这一背景，PayPal在未来几年有着强烈的增长雄心也就不足为奇了，其目标是到2025年通过现有业务的增长、更高的客户创造超过500亿美元的收入（是2020年收入的两倍多）参与度和新产品将增加PayPal的总目标市场。</blockquote></p><p> PayPal expects to double the number of active accounts over the next five years and triple the volumes transacted, which seems to be achievable considering its growth history and the strong growth prospects of the global payments industry.</p><p><blockquote>PayPal预计在未来五年内将活跃账户数量增加一倍，交易量增加两倍，考虑到其增长历史和全球支付行业的强劲增长前景，这似乎是可以实现的。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/828bae36490c031b69fcf87de3ef91a8\" tg-width=\"640\" tg-height=\"341\"><span>Source: PayPal.</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：PayPal。</span></p></blockquote></p><p> This means that $50 billion in revenue by 2025 represents CAGR of about 20% during 2020-25, showing that PayPal has very good growth prospects in coming years. Moreover, as the company expects to improve a little bit its business margins during this period, its earnings are expected to increase at CAGR of 22% over the next five years and generate more than $40 billion in free cash flow.</p><p><blockquote>这意味着到2025年收入将达到500亿美元，2020-25年的复合年增长率约为20%，这表明PayPal在未来几年具有非常好的增长前景。此外，由于该公司预计在此期间其业务利润率将略有提高，预计未来五年其盈利将以22%的复合年增长率增长，并产生超过400亿美元的自由现金流。</blockquote></p><p> <b>Financial Overview</b></p><p><blockquote><b>财务概况</b></blockquote></p><p> Regarding its financial performance, PayPal has a very good track record with revenues and earnings growing quite rapidly over the past few years. Indeed, from 201 to 2020, PayPal’s revenues increased at a CAGR of around 20% and its earnings increased at CAGR of 31%, a very impressive achievement and much better than established peers like Visa and MasterCard.</p><p><blockquote>就其财务业绩而言，PayPal拥有非常良好的业绩记录，过去几年的收入和盈利增长相当快。事实上，从201年到2020年，PayPal的收入复合年增长率约为20%，盈利复合年增长率为31%，这是一项非常令人印象深刻的成就，远好于Visa和MasterCard等老牌同行。</blockquote></p><p> More recently, the company’s growth was not interrupted by the coronavirus as the secular growth trends of e-commerce and cash displacement accelerated with the pandemic, being a very strong tailwind for the company’s growth.</p><p><blockquote>最近，该公司的增长并未因冠状病毒而中断，因为电子商务和现金置换的长期增长趋势随着疫情而加速，成为该公司增长的强劲推动力。</blockquote></p><p> In 2020, PayPal recorded record financial figures regarding its revenues, volumes, net new active accounts and earnings. Indeed, PayPal’s revenues increased by 20.8% YoY to $21.5 billion, a level that is very close to Visa’s annual revenues showing that PayPal has achieved a very large size despite being a much younger company. Beyond higher revenues, its business margins and free cash flow generation also improved, a very good performance compared to its peers that rely more on debit and credit card payments.</p><p><blockquote>2020年，PayPal在收入、销量、净新增活跃账户和盈利方面创下了创纪录的财务数据。事实上，PayPal的收入同比增长20.8%，达到215亿美元，这一水平非常接近Visa的年收入，这表明PayPal尽管是一家年轻得多的公司，但规模却非常大。除了收入增加之外，其业务利润率和自由现金流生成也有所改善，与更依赖借记卡和信用卡支付的同行相比，这是一个非常好的表现。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a6b1369e32917090ea7cdb92b9a2fe8a\" tg-width=\"772\" tg-height=\"359\"><span>Source: PayPal.</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：PayPal。</span></p></blockquote></p><p> This positive financial performance was justified by the shift to online shopping and transactions due to Covid-19, but also due to PayPal’s new offerings such as the option to buy and hold digital currencies during the last quarter of the year. Its net income amounted to $4.2 billion, an increase of 70% YoY, boosted by organic growth and gains on some investments and its free cash flow was about $5 billion, or 23% of revenue, which shows that PayPal has a very good cash flow generation capacity.</p><p><blockquote>这种积极的财务表现是合理的，因为Covid-19导致人们转向在线购物和交易，但也得益于PayPal在今年最后一个季度推出的新产品，例如购买和持有数字货币的选项。在有机增长和部分投资收益的推动下，其净利润达42亿美元，同比增长70%，自由现金流约为50亿美元，占收入的23%，这表明PayPal拥有非常好的现金流生成能力。</blockquote></p><p> During thefirst quarter of 2021, PayPal has maintained an impressive operating momentum with volumes up by 50% YoY and revenue up by 31% YoY. Active accounts grew by 21% to 392 million, while it added 14.5 million net new accounts during the quarter. Its operating margin improved to 27.7% (non-GAAP) and non-GAAP EPS grew by 84% YoY and free cash flow amounted to $1.54 billion or 25% of its quarterly revenue.</p><p><blockquote>2021年第一季度，PayPal保持了令人印象深刻的运营势头，销量同比增长50%，收入同比增长31%。活跃账户增长21%，达到3.92亿，本季度净新增账户1450万。其营业利润率提高至27.7%（非GAAP），非GAAP每股收益同比增长84%，自由现金流达15.4亿美元，占季度收入的25%。</blockquote></p><p> For the full year 2021, its guidance was revised upwards with Q1 earnings and PayPal now expects to grow revenues to about $25.7 billion, which represents annual growth of about 20% in constant currencies, EPS growth around 21% YoY and about $6 billion in free cash flow.</p><p><blockquote>对于2021年全年，其指引随着第一季度收益而上调，PayPal目前预计收入将增长至约257亿美元，按固定汇率计算，年增长率约为20%，每股收益同比增长约21%，自由现金流约为60亿美元。</blockquote></p><p> This clearly shows that PayPal’s growth momentum is not showing any sign of slowdown over the coming quarters, boding quite well to reach its 2025 targets probably ahead of schedule if it continues to grow at this pace.</p><p><blockquote>这清楚地表明，PayPal的增长势头在未来几个季度没有显示出任何放缓的迹象，如果继续以这种速度增长，很可能会提前实现2025年的目标。</blockquote></p><p> However, this is not currently expected from the sell-side, given that according toanalysts’ estimates, revenue growth is expected to be around 20-21% during the next 2-3 years and then slow down a little bit to less than 20% in 2024 and 2025. This is in-line with PayPal’s own targets, which means that there is some potential upside to estimates if it continues to execute well on its growth initiatives during the next few years.</p><p><blockquote>然而，目前卖方预计不会出现这种情况，因为根据分析师的估计，未来2-3年收入增长预计在20-21%左右，然后略有放缓至20%以下。2024年和2025年。这符合PayPal自己的目标，这意味着如果它在未来几年继续良好地执行其增长计划，估计还有一些潜在的上行空间。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9ee830ca42c6ed20907df39e8c28786b\" tg-width=\"902\" tg-height=\"250\"><span>Source: SeekingAlpha.</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：SeekingAlpha。</span></p></blockquote></p><p></p><p> Regarding its capital allocation, PayPal’s has used its cash flow generation capacity to finance several acquisitions and repurchase its own shares, while capex spending has been relatively limited as expected for a technology company that operates digitally. Going forward, this strategy is not expected to change much as PayPal should continue to invest in fintech innovation through PayPal Ventures, while share buybacks will be the main way to return capital to shareholders even though the company may decide to start distributing dividends in the coming years.</p><p><blockquote>在资本配置方面，PayPal百货利用其现金流产生能力为多项收购和回购自己的股票提供资金，而资本支出支出相对有限，正如一家数字化运营的科技公司所预期的那样。展望未来，这一战略预计不会发生太大变化，因为PayPal应该继续通过PayPal风险投资公司投资金融科技创新，而股票回购将是向股东返还资本的主要方式，尽管该公司可能决定在未来几年开始分配股息。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/530c58f1461ce1f7eefb7856a4ef2d05\" tg-width=\"563\" tg-height=\"318\"><span>Source: PayPal.</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：PayPal。</span></p></blockquote></p><p> <b>Conclusion</b></p><p><blockquote><b>结论</b></blockquote></p><p> PayPal has a very good business and its growth prospects are very strong, both from industry tailwinds and its own growth initiatives. I think this is one of the best ways to play the secular growth trend of digital payments, as PayPal’s business model is completely focused on digital channels while its closest competitors Visa or Mastercard still rely significantly in physical transactions.</p><p><blockquote>PayPal拥有非常好的业务，其增长前景非常强劲，这既来自行业推动力，也来自其自身的增长举措。我认为这是发挥数字支付长期增长趋势的最佳方式之一，因为PayPal的商业模式完全专注于数字渠道，而其最接近的竞争对手Visa或Mastercard仍然严重依赖实体交易。</blockquote></p><p> This profile justifies PayPal’s premium valuation, considering that it is currentlytrading at about 57x forward earnings, while Visa and Mastercard are trading at between 42-47x earnings. Regarding my personal portfolio, I’ve recently rebalanced my positions and PayPal is now my largest holding on the digital payments theme, as I see this company as a very compelling long-term play in this industry.</p><p><blockquote>考虑到PayPal目前的预期市盈率约为57倍，而Visa和万事达卡的市盈率在42-47倍之间，这一情况证明了其溢价估值的合理性。关于我的个人投资组合，我最近重新平衡了我的头寸，PayPal现在是我在数字支付主题上最大的持股，因为我认为这家公司是该行业中非常引人注目的长期投资。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PayPal: One Of The Best Plays On The Secular Growth Trend Of Digital Payments<blockquote>PayPal：数字支付长期增长趋势的最佳剧本之一</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPayPal: One Of The Best Plays On The Secular Growth Trend Of Digital Payments<blockquote>PayPal：数字支付长期增长趋势的最佳剧本之一</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">seekingalpha</strong><span class=\"h-time small\">2021-06-14 14:36</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>PayPal is a leading fintech company that benefits immensely from the secular growth trend in the digital payments industry.</li>  <li>Its growth history is impressive and momentum is not showing any sign of slowing down, making its 2025 targets quite achievable.</li>  <li>The premium valuation to Visa or Mastercard is justified and PayPal is now my largest holding in the digital payments theme.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/aa4976c13e5ffab4c5035b08d60831ed\" tg-width=\"768\" tg-height=\"512\"><span>JasonDoiy/iStock Unreleased via Getty Images</span></p><p><blockquote><ul><li>PayPal是一家领先的金融科技公司，从数字支付行业的长期增长趋势中受益匪浅。</li><li>其增长历史令人印象深刻，而且势头没有任何放缓的迹象，这使得其2025年的目标完全可以实现。</li><li>Visa或Mastercard的溢价估值是合理的，PayPal现在是我在数字支付主题中最大的持股。</li></ul><p class=\"t-img-caption\"><span>JasonDoiy/iStock未通过Getty Images发布</span></p></blockquote></p><p> <b>PayPal</b>(PYPL) is a compelling long-term play on the secular growth trend of digital payments as the company’s growth path is likely to remain quite strong over the next few years.</p><p><blockquote><b>PayPal</b>（PYPL）是数字支付长期增长趋势中引人注目的长期投资，因为该公司的增长路径在未来几年可能会保持相当强劲。</blockquote></p><p> <b>Company Profile</b></p><p><blockquote><b>公司简介</b></blockquote></p><p> PayPal Holdings Inc. is a leading fintech company that enables digital and mobile payments through its technology platform. Its major competitors are other payment technology companies, such as<b>Visa</b>(V),<b>Mastercard</b>(MA) or<b>Adyen</b>(OTCPK:ADYEY). It currently has a market capitalization of about $309 billion, a smaller value than MasterCard or Visa.</p><p><blockquote>PayPal控股公司是一家领先的金融科技公司，通过其技术平台实现数字和移动支付。其主要竞争对手是其他支付技术公司，如<b>签证</b>(V)，<b>万事达卡</b>（MA）或<b>Adyen</b>（OTCPK：ADYEY）。它目前的市值约为3090亿美元，低于万事达卡或Visa。</blockquote></p><p> PayPal’s core business is the offering of payment solutions to merchants and consumers, operating globally. At the end of 2020, it had about 377 million active accounts, of which some 348 million consumer accounts and 29 million merchant accounts, more than double the number of active accounts at the end of 2015.</p><p><blockquote>PayPal的核心业务是向商家和消费者提供支付解决方案，业务遍及全球。截至2020年底，其拥有约3.77亿活跃账户，其中约3.48亿消费者账户和2900万商家账户，是2015年底活跃账户数量的两倍多。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/45f478cd622b0c634fd146fdf46bf0ef\" tg-width=\"747\" tg-height=\"432\"><span>Source: PayPal.</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：PayPal。</span></p></blockquote></p><p> The company’s revenue stream comes mainly from charging fees for some completed payment transactions, while generally it does not charge consumers to fund or withdraw money from their PayPal account. It also generates revenues from currency conversion and instant transfers from the PayPal or Venmo accounts to debit cards or bank accounts. For its merchant clients, it also offers access to certain credit products for small and medium-sized merchants, increasing its engagement its clients and providing finance for clients that possibly would not get loans from traditional banks or other lending providers.</p><p><blockquote>该公司的收入来源主要来自对一些已完成的支付交易收取费用，而通常不会向消费者收取从其PayPal账户中提供资金或提款的费用。它还通过货币兑换和从PayPal或Venmo账户到借记卡或银行账户的即时转账产生收入。对于其商户客户，它还为中小型商户提供某些信贷产品，增加其客户参与度，并为可能无法从传统银行或其他贷款提供商获得贷款的客户提供融资。</blockquote></p><p> <b>Secular Growth</b></p><p><blockquote><b>长期增长</b></blockquote></p><p> As I’ve analyzed in a previous article on “Visa: Despite Earnings Dip, Secular Growth Prospects Remain Strong,” the global payments industry has a very good growth track record and future growth prospects are quite strong.</p><p><blockquote>正如我在上一篇关于“Visa：尽管盈利下降，长期增长前景依然强劲”的文章中所分析的那样，全球支付行业拥有非常好的增长记录，未来的增长前景也相当强劲。</blockquote></p><p> During the past few years, consumers and businesses have increasingly adopted new payment methods beyond cash and the rise of e-commerce has also been an important growth driver of digital payments across the globe. Revenues for the industry have grown roughly at 7% per year over recent years, to a total of just under $2 trillion in 2019, according to McKinsey data, and this growth is only expected to accelerate in the future as digital payments continue to increase their market share as a percentage of total banking revenues.</p><p><blockquote>在过去几年中，消费者和企业越来越多地采用现金以外的新支付方式，电子商务的兴起也是全球数字支付的重要增长动力。根据麦肯锡的数据，近年来该行业的收入以每年约7%的速度增长，2019年总额略低于2万亿美元，而且随着数字支付继续增加，这种增长预计未来只会加速。市场份额占银行总收入的百分比。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d27b37a2ed30f39bff844ae07aa49ac5\" tg-width=\"372\" tg-height=\"395\"><span>Source: McKinsey.</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：麦肯锡。</span></p></blockquote></p><p> This background has been very supportive for PayPal’s growth prospects, as one of the leading companies in this industry. Indeed, PayPal’s revenues have increased at a compounded annual growth rate [CAGR] of 20.8% during the past five years, a much higher growth rate than the global payments industry and also above its largest competitors like Visa and MasterCard.</p><p><blockquote>作为该行业的领先公司之一，这一背景非常支持PayPal的增长前景。事实上，PayPal的收入在过去五年中以20.8%的复合年增长率[CAGR]增长，远高于全球支付行业的增长率，也高于Visa和MasterCard等最大竞争对手。</blockquote></p><p> Moreover, while recently the growth path of digital payments has changed due to the coronavirus pandemic, that has affected negatively the growth of the global payments industry, PayPal has remained on a strong growth path because its business is clearly more exposed to digital transactions rather than physical payments. This means that the pandemic has barely impacted its business, while it has been a significant setback for other companies, such as&nbsp;<b>American Express</b>&nbsp;(AXP) or MasterCard that are more exposed to cross-border transactions.</p><p><blockquote>此外，虽然最近由于冠状病毒大流行，数字支付的增长路径发生了变化，这对全球支付行业的增长产生了负面影响，但PayPal仍然处于强劲的增长路径上，因为其业务显然更多地暴露于数字交易而不是实物支付。这意味着疫情几乎没有影响其业务，而对其他公司来说却是一个重大挫折，例如<b>美国运通</b>（AXP）或万事达卡更容易进行跨境交易。</blockquote></p><p> Nevertheless, the Covid-19 seems to be positive for the long-term growth of the industry because digital payments became more adopted last year and people will likely use less cash for payment transactions in the future, accelerating even further the growth of digital payments across the world.</p><p><blockquote>尽管如此，新冠肺炎似乎对该行业的长期增长是积极的，因为去年数字支付被更多地采用，人们在未来可能会减少使用现金进行支付交易，从而进一步加速全球数字支付的增长。</blockquote></p><p> Over the next few years, growth is expected to resume quite rapidly and should even be higher than in the recent past. According to Mordor Intelligence, the global digital payments industry is expected to have a revenue CAGR of 13.7% during 2021-26, which is almost double the growth in recent years. This clearly shows that digital payments is a secular growth industry, being a very good backdrop for the companies operating in this industry for years to come.</p><p><blockquote>在未来几年，预计增长将相当迅速地恢复，甚至应该高于最近的过去。根据Mordor Intelligence的数据，预计2021-26年全球数字支付行业的收入CAGR将达到13.7%，几乎是近年来增长的两倍。这清楚地表明，数字支付是一个长期增长的行业，对于未来几年在该行业运营的公司来说是一个非常好的背景。</blockquote></p><p></p><p> Taking this environment into account, PayPal is clearly in a very good position to maintain a solid growth path for many years to come, being potentially one of the major winners of the global shift to digital payments and e-commerce.</p><p><blockquote>考虑到这种环境，PayPal显然处于非常有利的地位，可以在未来许多年保持稳健的增长道路，有可能成为全球向数字支付和电子商务转变的主要赢家之一。</blockquote></p><p> Taking this background into account, it is not surprising that PayPal has strong growth ambitions for the coming years, aiming to generate more than $50 billion in revenue by 2025 (more than double the 2020 revenues) both from growth of its existing business, higher customer engagement and new offerings that will increase PayPal’s total addressable market.</p><p><blockquote>考虑到这一背景，PayPal在未来几年有着强烈的增长雄心也就不足为奇了，其目标是到2025年通过现有业务的增长、更高的客户创造超过500亿美元的收入（是2020年收入的两倍多）参与度和新产品将增加PayPal的总目标市场。</blockquote></p><p> PayPal expects to double the number of active accounts over the next five years and triple the volumes transacted, which seems to be achievable considering its growth history and the strong growth prospects of the global payments industry.</p><p><blockquote>PayPal预计在未来五年内将活跃账户数量增加一倍，交易量增加两倍，考虑到其增长历史和全球支付行业的强劲增长前景，这似乎是可以实现的。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/828bae36490c031b69fcf87de3ef91a8\" tg-width=\"640\" tg-height=\"341\"><span>Source: PayPal.</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：PayPal。</span></p></blockquote></p><p> This means that $50 billion in revenue by 2025 represents CAGR of about 20% during 2020-25, showing that PayPal has very good growth prospects in coming years. Moreover, as the company expects to improve a little bit its business margins during this period, its earnings are expected to increase at CAGR of 22% over the next five years and generate more than $40 billion in free cash flow.</p><p><blockquote>这意味着到2025年收入将达到500亿美元，2020-25年的复合年增长率约为20%，这表明PayPal在未来几年具有非常好的增长前景。此外，由于该公司预计在此期间其业务利润率将略有提高，预计未来五年其盈利将以22%的复合年增长率增长，并产生超过400亿美元的自由现金流。</blockquote></p><p> <b>Financial Overview</b></p><p><blockquote><b>财务概况</b></blockquote></p><p> Regarding its financial performance, PayPal has a very good track record with revenues and earnings growing quite rapidly over the past few years. Indeed, from 201 to 2020, PayPal’s revenues increased at a CAGR of around 20% and its earnings increased at CAGR of 31%, a very impressive achievement and much better than established peers like Visa and MasterCard.</p><p><blockquote>就其财务业绩而言，PayPal拥有非常良好的业绩记录，过去几年的收入和盈利增长相当快。事实上，从201年到2020年，PayPal的收入复合年增长率约为20%，盈利复合年增长率为31%，这是一项非常令人印象深刻的成就，远好于Visa和MasterCard等老牌同行。</blockquote></p><p> More recently, the company’s growth was not interrupted by the coronavirus as the secular growth trends of e-commerce and cash displacement accelerated with the pandemic, being a very strong tailwind for the company’s growth.</p><p><blockquote>最近，该公司的增长并未因冠状病毒而中断，因为电子商务和现金置换的长期增长趋势随着疫情而加速，成为该公司增长的强劲推动力。</blockquote></p><p> In 2020, PayPal recorded record financial figures regarding its revenues, volumes, net new active accounts and earnings. Indeed, PayPal’s revenues increased by 20.8% YoY to $21.5 billion, a level that is very close to Visa’s annual revenues showing that PayPal has achieved a very large size despite being a much younger company. Beyond higher revenues, its business margins and free cash flow generation also improved, a very good performance compared to its peers that rely more on debit and credit card payments.</p><p><blockquote>2020年，PayPal在收入、销量、净新增活跃账户和盈利方面创下了创纪录的财务数据。事实上，PayPal的收入同比增长20.8%，达到215亿美元，这一水平非常接近Visa的年收入，这表明PayPal尽管是一家年轻得多的公司，但规模却非常大。除了收入增加之外，其业务利润率和自由现金流生成也有所改善，与更依赖借记卡和信用卡支付的同行相比，这是一个非常好的表现。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a6b1369e32917090ea7cdb92b9a2fe8a\" tg-width=\"772\" tg-height=\"359\"><span>Source: PayPal.</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：PayPal。</span></p></blockquote></p><p> This positive financial performance was justified by the shift to online shopping and transactions due to Covid-19, but also due to PayPal’s new offerings such as the option to buy and hold digital currencies during the last quarter of the year. Its net income amounted to $4.2 billion, an increase of 70% YoY, boosted by organic growth and gains on some investments and its free cash flow was about $5 billion, or 23% of revenue, which shows that PayPal has a very good cash flow generation capacity.</p><p><blockquote>这种积极的财务表现是合理的，因为Covid-19导致人们转向在线购物和交易，但也得益于PayPal在今年最后一个季度推出的新产品，例如购买和持有数字货币的选项。在有机增长和部分投资收益的推动下，其净利润达42亿美元，同比增长70%，自由现金流约为50亿美元，占收入的23%，这表明PayPal拥有非常好的现金流生成能力。</blockquote></p><p> During thefirst quarter of 2021, PayPal has maintained an impressive operating momentum with volumes up by 50% YoY and revenue up by 31% YoY. Active accounts grew by 21% to 392 million, while it added 14.5 million net new accounts during the quarter. Its operating margin improved to 27.7% (non-GAAP) and non-GAAP EPS grew by 84% YoY and free cash flow amounted to $1.54 billion or 25% of its quarterly revenue.</p><p><blockquote>2021年第一季度，PayPal保持了令人印象深刻的运营势头，销量同比增长50%，收入同比增长31%。活跃账户增长21%，达到3.92亿，本季度净新增账户1450万。其营业利润率提高至27.7%（非GAAP），非GAAP每股收益同比增长84%，自由现金流达15.4亿美元，占季度收入的25%。</blockquote></p><p> For the full year 2021, its guidance was revised upwards with Q1 earnings and PayPal now expects to grow revenues to about $25.7 billion, which represents annual growth of about 20% in constant currencies, EPS growth around 21% YoY and about $6 billion in free cash flow.</p><p><blockquote>对于2021年全年，其指引随着第一季度收益而上调，PayPal目前预计收入将增长至约257亿美元，按固定汇率计算，年增长率约为20%，每股收益同比增长约21%，自由现金流约为60亿美元。</blockquote></p><p> This clearly shows that PayPal’s growth momentum is not showing any sign of slowdown over the coming quarters, boding quite well to reach its 2025 targets probably ahead of schedule if it continues to grow at this pace.</p><p><blockquote>这清楚地表明，PayPal的增长势头在未来几个季度没有显示出任何放缓的迹象，如果继续以这种速度增长，很可能会提前实现2025年的目标。</blockquote></p><p> However, this is not currently expected from the sell-side, given that according toanalysts’ estimates, revenue growth is expected to be around 20-21% during the next 2-3 years and then slow down a little bit to less than 20% in 2024 and 2025. This is in-line with PayPal’s own targets, which means that there is some potential upside to estimates if it continues to execute well on its growth initiatives during the next few years.</p><p><blockquote>然而，目前卖方预计不会出现这种情况，因为根据分析师的估计，未来2-3年收入增长预计在20-21%左右，然后略有放缓至20%以下。2024年和2025年。这符合PayPal自己的目标，这意味着如果它在未来几年继续良好地执行其增长计划，估计还有一些潜在的上行空间。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9ee830ca42c6ed20907df39e8c28786b\" tg-width=\"902\" tg-height=\"250\"><span>Source: SeekingAlpha.</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：SeekingAlpha。</span></p></blockquote></p><p></p><p> Regarding its capital allocation, PayPal’s has used its cash flow generation capacity to finance several acquisitions and repurchase its own shares, while capex spending has been relatively limited as expected for a technology company that operates digitally. Going forward, this strategy is not expected to change much as PayPal should continue to invest in fintech innovation through PayPal Ventures, while share buybacks will be the main way to return capital to shareholders even though the company may decide to start distributing dividends in the coming years.</p><p><blockquote>在资本配置方面，PayPal百货利用其现金流产生能力为多项收购和回购自己的股票提供资金，而资本支出支出相对有限，正如一家数字化运营的科技公司所预期的那样。展望未来，这一战略预计不会发生太大变化，因为PayPal应该继续通过PayPal风险投资公司投资金融科技创新，而股票回购将是向股东返还资本的主要方式，尽管该公司可能决定在未来几年开始分配股息。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/530c58f1461ce1f7eefb7856a4ef2d05\" tg-width=\"563\" tg-height=\"318\"><span>Source: PayPal.</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：PayPal。</span></p></blockquote></p><p> <b>Conclusion</b></p><p><blockquote><b>结论</b></blockquote></p><p> PayPal has a very good business and its growth prospects are very strong, both from industry tailwinds and its own growth initiatives. I think this is one of the best ways to play the secular growth trend of digital payments, as PayPal’s business model is completely focused on digital channels while its closest competitors Visa or Mastercard still rely significantly in physical transactions.</p><p><blockquote>PayPal拥有非常好的业务，其增长前景非常强劲，这既来自行业推动力，也来自其自身的增长举措。我认为这是发挥数字支付长期增长趋势的最佳方式之一，因为PayPal的商业模式完全专注于数字渠道，而其最接近的竞争对手Visa或Mastercard仍然严重依赖实体交易。</blockquote></p><p> This profile justifies PayPal’s premium valuation, considering that it is currentlytrading at about 57x forward earnings, while Visa and Mastercard are trading at between 42-47x earnings. Regarding my personal portfolio, I’ve recently rebalanced my positions and PayPal is now my largest holding on the digital payments theme, as I see this company as a very compelling long-term play in this industry.</p><p><blockquote>考虑到PayPal目前的预期市盈率约为57倍，而Visa和万事达卡的市盈率在42-47倍之间，这一情况证明了其溢价估值的合理性。关于我的个人投资组合，我最近重新平衡了我的头寸，PayPal现在是我在数字支付主题上最大的持股，因为我认为这家公司是该行业中非常引人注目的长期投资。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/article/4434455-paypal-best-play-on-secular-growth-trend-of-digital-payments\">seekingalpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PYPL":"PayPal"},"source_url":"https://seekingalpha.com/article/4434455-paypal-best-play-on-secular-growth-trend-of-digital-payments","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141995531","content_text":"Summary\n\nPayPal is a leading fintech company that benefits immensely from the secular growth trend in the digital payments industry.\nIts growth history is impressive and momentum is not showing any sign of slowing down, making its 2025 targets quite achievable.\nThe premium valuation to Visa or Mastercard is justified and PayPal is now my largest holding in the digital payments theme.\n\nJasonDoiy/iStock Unreleased via Getty Images\nPayPal(PYPL) is a compelling long-term play on the secular growth trend of digital payments as the company’s growth path is likely to remain quite strong over the next few years.\nCompany Profile\nPayPal Holdings Inc. is a leading fintech company that enables digital and mobile payments through its technology platform. Its major competitors are other payment technology companies, such asVisa(V),Mastercard(MA) orAdyen(OTCPK:ADYEY). It currently has a market capitalization of about $309 billion, a smaller value than MasterCard or Visa.\nPayPal’s core business is the offering of payment solutions to merchants and consumers, operating globally. At the end of 2020, it had about 377 million active accounts, of which some 348 million consumer accounts and 29 million merchant accounts, more than double the number of active accounts at the end of 2015.\nSource: PayPal.\nThe company’s revenue stream comes mainly from charging fees for some completed payment transactions, while generally it does not charge consumers to fund or withdraw money from their PayPal account. It also generates revenues from currency conversion and instant transfers from the PayPal or Venmo accounts to debit cards or bank accounts. For its merchant clients, it also offers access to certain credit products for small and medium-sized merchants, increasing its engagement its clients and providing finance for clients that possibly would not get loans from traditional banks or other lending providers.\nSecular Growth\nAs I’ve analyzed in a previous article on “Visa: Despite Earnings Dip, Secular Growth Prospects Remain Strong,” the global payments industry has a very good growth track record and future growth prospects are quite strong.\nDuring the past few years, consumers and businesses have increasingly adopted new payment methods beyond cash and the rise of e-commerce has also been an important growth driver of digital payments across the globe. Revenues for the industry have grown roughly at 7% per year over recent years, to a total of just under $2 trillion in 2019, according to McKinsey data, and this growth is only expected to accelerate in the future as digital payments continue to increase their market share as a percentage of total banking revenues.\nSource: McKinsey.\nThis background has been very supportive for PayPal’s growth prospects, as one of the leading companies in this industry. Indeed, PayPal’s revenues have increased at a compounded annual growth rate [CAGR] of 20.8% during the past five years, a much higher growth rate than the global payments industry and also above its largest competitors like Visa and MasterCard.\nMoreover, while recently the growth path of digital payments has changed due to the coronavirus pandemic, that has affected negatively the growth of the global payments industry, PayPal has remained on a strong growth path because its business is clearly more exposed to digital transactions rather than physical payments. This means that the pandemic has barely impacted its business, while it has been a significant setback for other companies, such as American Express (AXP) or MasterCard that are more exposed to cross-border transactions.\nNevertheless, the Covid-19 seems to be positive for the long-term growth of the industry because digital payments became more adopted last year and people will likely use less cash for payment transactions in the future, accelerating even further the growth of digital payments across the world.\nOver the next few years, growth is expected to resume quite rapidly and should even be higher than in the recent past. According to Mordor Intelligence, the global digital payments industry is expected to have a revenue CAGR of 13.7% during 2021-26, which is almost double the growth in recent years. This clearly shows that digital payments is a secular growth industry, being a very good backdrop for the companies operating in this industry for years to come.\nTaking this environment into account, PayPal is clearly in a very good position to maintain a solid growth path for many years to come, being potentially one of the major winners of the global shift to digital payments and e-commerce.\nTaking this background into account, it is not surprising that PayPal has strong growth ambitions for the coming years, aiming to generate more than $50 billion in revenue by 2025 (more than double the 2020 revenues) both from growth of its existing business, higher customer engagement and new offerings that will increase PayPal’s total addressable market.\nPayPal expects to double the number of active accounts over the next five years and triple the volumes transacted, which seems to be achievable considering its growth history and the strong growth prospects of the global payments industry.\nSource: PayPal.\nThis means that $50 billion in revenue by 2025 represents CAGR of about 20% during 2020-25, showing that PayPal has very good growth prospects in coming years. Moreover, as the company expects to improve a little bit its business margins during this period, its earnings are expected to increase at CAGR of 22% over the next five years and generate more than $40 billion in free cash flow.\nFinancial Overview\nRegarding its financial performance, PayPal has a very good track record with revenues and earnings growing quite rapidly over the past few years. Indeed, from 201 to 2020, PayPal’s revenues increased at a CAGR of around 20% and its earnings increased at CAGR of 31%, a very impressive achievement and much better than established peers like Visa and MasterCard.\nMore recently, the company’s growth was not interrupted by the coronavirus as the secular growth trends of e-commerce and cash displacement accelerated with the pandemic, being a very strong tailwind for the company’s growth.\nIn 2020, PayPal recorded record financial figures regarding its revenues, volumes, net new active accounts and earnings. Indeed, PayPal’s revenues increased by 20.8% YoY to $21.5 billion, a level that is very close to Visa’s annual revenues showing that PayPal has achieved a very large size despite being a much younger company. Beyond higher revenues, its business margins and free cash flow generation also improved, a very good performance compared to its peers that rely more on debit and credit card payments.\nSource: PayPal.\nThis positive financial performance was justified by the shift to online shopping and transactions due to Covid-19, but also due to PayPal’s new offerings such as the option to buy and hold digital currencies during the last quarter of the year. Its net income amounted to $4.2 billion, an increase of 70% YoY, boosted by organic growth and gains on some investments and its free cash flow was about $5 billion, or 23% of revenue, which shows that PayPal has a very good cash flow generation capacity.\nDuring thefirst quarter of 2021, PayPal has maintained an impressive operating momentum with volumes up by 50% YoY and revenue up by 31% YoY. Active accounts grew by 21% to 392 million, while it added 14.5 million net new accounts during the quarter. Its operating margin improved to 27.7% (non-GAAP) and non-GAAP EPS grew by 84% YoY and free cash flow amounted to $1.54 billion or 25% of its quarterly revenue.\nFor the full year 2021, its guidance was revised upwards with Q1 earnings and PayPal now expects to grow revenues to about $25.7 billion, which represents annual growth of about 20% in constant currencies, EPS growth around 21% YoY and about $6 billion in free cash flow.\nThis clearly shows that PayPal’s growth momentum is not showing any sign of slowdown over the coming quarters, boding quite well to reach its 2025 targets probably ahead of schedule if it continues to grow at this pace.\nHowever, this is not currently expected from the sell-side, given that according toanalysts’ estimates, revenue growth is expected to be around 20-21% during the next 2-3 years and then slow down a little bit to less than 20% in 2024 and 2025. This is in-line with PayPal’s own targets, which means that there is some potential upside to estimates if it continues to execute well on its growth initiatives during the next few years.\nSource: SeekingAlpha.\nRegarding its capital allocation, PayPal’s has used its cash flow generation capacity to finance several acquisitions and repurchase its own shares, while capex spending has been relatively limited as expected for a technology company that operates digitally. Going forward, this strategy is not expected to change much as PayPal should continue to invest in fintech innovation through PayPal Ventures, while share buybacks will be the main way to return capital to shareholders even though the company may decide to start distributing dividends in the coming years.\nSource: PayPal.\nConclusion\nPayPal has a very good business and its growth prospects are very strong, both from industry tailwinds and its own growth initiatives. I think this is one of the best ways to play the secular growth trend of digital payments, as PayPal’s business model is completely focused on digital channels while its closest competitors Visa or Mastercard still rely significantly in physical transactions.\nThis profile justifies PayPal’s premium valuation, considering that it is currentlytrading at about 57x forward earnings, while Visa and Mastercard are trading at between 42-47x earnings. Regarding my personal portfolio, I’ve recently rebalanced my positions and PayPal is now my largest holding on the digital payments theme, as I see this company as a very compelling long-term play in this industry.","news_type":1,"symbols_score_info":{"PYPL":0.9}},"isVote":1,"tweetType":1,"viewCount":727,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185215445,"gmtCreate":1623652885087,"gmtModify":1634030607279,"author":{"id":"3575704006877751","authorId":"3575704006877751","name":"oyzheng","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575704006877751","idStr":"3575704006877751"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185215445","repostId":"1146430910","repostType":4,"isVote":1,"tweetType":1,"viewCount":1360,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185215546,"gmtCreate":1623652860685,"gmtModify":1634030607401,"author":{"id":"3575704006877751","authorId":"3575704006877751","name":"oyzheng","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575704006877751","idStr":"3575704006877751"},"themes":[],"htmlText":"I agree","listText":"I agree","text":"I agree","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185215546","repostId":"1165811803","repostType":4,"isVote":1,"tweetType":1,"viewCount":2012,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":186974421,"gmtCreate":1623471511163,"gmtModify":1634032682652,"author":{"id":"3575704006877751","authorId":"3575704006877751","name":"oyzheng","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575704006877751","idStr":"3575704006877751"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/186974421","repostId":"2142744202","repostType":4,"isVote":1,"tweetType":1,"viewCount":820,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":186978096,"gmtCreate":1623471276015,"gmtModify":1634032686910,"author":{"id":"3575704006877751","authorId":"3575704006877751","name":"oyzheng","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575704006877751","idStr":"3575704006877751"},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/186978096","repostId":"2142202662","repostType":4,"isVote":1,"tweetType":1,"viewCount":2061,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":186971956,"gmtCreate":1623471250975,"gmtModify":1634032687856,"author":{"id":"3575704006877751","authorId":"3575704006877751","name":"oyzheng","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575704006877751","idStr":"3575704006877751"},"themes":[],"htmlText":"Good info","listText":"Good info","text":"Good info","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/186971956","repostId":"1177806573","repostType":4,"isVote":1,"tweetType":1,"viewCount":2385,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}